NewLink Genetics Corporation (NLNK) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of NewLink Genetics Corporation (NASDAQ:NLNK) from a buy rating to a hold rating in a research report released on Wednesday morning.

According to Zacks, “NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. “

Several other research analysts also recently commented on the company. Jefferies Group LLC decreased their price objective on NewLink Genetics Corporation from $26.00 to $25.00 and set a buy rating on the stock in a report on Friday, November 3rd. Stifel Nicolaus lifted their price objective on NewLink Genetics Corporation from $25.00 to $29.00 and gave the stock a buy rating in a report on Friday, November 3rd. Cantor Fitzgerald restated a buy rating and set a $26.00 price target on shares of NewLink Genetics Corporation in a report on Thursday, November 2nd. Bank of America Corporation assumed coverage on NewLink Genetics Corporation in a report on Friday, October 13th. They set a buy rating and a $22.00 price target on the stock. Finally, ValuEngine downgraded NewLink Genetics Corporation from a sell rating to a strong sell rating in a report on Tuesday, September 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. NewLink Genetics Corporation currently has a consensus rating of Buy and an average price target of $23.43.

NewLink Genetics Corporation (NASDAQ:NLNK) traded up $0.15 on Wednesday, hitting $9.02. The stock had a trading volume of 1,035,500 shares, compared to its average volume of 1,307,983. NewLink Genetics Corporation has a 1 year low of $5.90 and a 1 year high of $25.17.

ILLEGAL ACTIVITY WARNING: This article was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://transcriptdaily.com/2017/11/11/newlink-genetics-corporation-nlnk-downgraded-by-zacks-investment-research.html.

In other NewLink Genetics Corporation news, major shareholder Stine Seed Farm, Inc. purchased 780,487 shares of NewLink Genetics Corporation stock in a transaction that occurred on Friday, October 6th. The shares were bought at an average price of $10.25 per share, for a total transaction of $7,999,991.75. Following the acquisition, the insider now directly owns 7,857,732 shares in the company, valued at $80,541,753. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 13.70% of the stock is owned by insiders.

A number of large investors have recently made changes to their positions in NLNK. UBS Asset Management Americas Inc. bought a new stake in NewLink Genetics Corporation during the 1st quarter valued at approximately $297,000. Parametric Portfolio Associates LLC bought a new stake in NewLink Genetics Corporation during the 1st quarter valued at approximately $555,000. Prudential Financial Inc. bought a new stake in NewLink Genetics Corporation during the 1st quarter valued at approximately $443,000. American International Group Inc. boosted its position in NewLink Genetics Corporation by 7.1% during the 1st quarter. American International Group Inc. now owns 13,321 shares of the biotechnology company’s stock valued at $321,000 after acquiring an additional 880 shares in the last quarter. Finally, Teachers Advisors LLC boosted its position in NewLink Genetics Corporation by 3.0% during the 1st quarter. Teachers Advisors LLC now owns 207,854 shares of the biotechnology company’s stock valued at $5,009,000 after acquiring an additional 6,047 shares in the last quarter. Institutional investors own 55.30% of the company’s stock.

NewLink Genetics Corporation Company Profile

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.

Get a free copy of the Zacks research report on NewLink Genetics Corporation (NLNK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NewLink Genetics Corporation (NASDAQ:NLNK)

Receive News & Ratings for NewLink Genetics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply